IL153586A0 - Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer - Google Patents

Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer

Info

Publication number
IL153586A0
IL153586A0 IL15358601A IL15358601A IL153586A0 IL 153586 A0 IL153586 A0 IL 153586A0 IL 15358601 A IL15358601 A IL 15358601A IL 15358601 A IL15358601 A IL 15358601A IL 153586 A0 IL153586 A0 IL 153586A0
Authority
IL
Israel
Prior art keywords
patients
cancer
radiosensitizers
vitamin
diagnosis
Prior art date
Application number
IL15358601A
Original Assignee
Ward Page Faulk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ward Page Faulk filed Critical Ward Page Faulk
Publication of IL153586A0 publication Critical patent/IL153586A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15358601A 2000-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer IL153586A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21438800P 2000-06-28 2000-06-28
US21442700P 2000-06-28 2000-06-28
US21438900P 2000-06-28 2000-06-28
PCT/US2001/020444 WO2002000170A2 (en) 2000-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
IL153586A0 true IL153586A0 (en) 2003-07-06

Family

ID=27395985

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15358601A IL153586A0 (en) 2000-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer

Country Status (6)

Country Link
EP (1) EP1305051A4 (en)
JP (1) JP2004501171A (en)
AU (1) AU2001271525A1 (en)
CA (1) CA2414401A1 (en)
IL (1) IL153586A0 (en)
WO (1) WO2002000170A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404334A4 (en) * 2001-05-15 2005-02-02 Faulk Pharmaceuticals Inc Targeted delivery of bioaffecting compounds for the treatment of cancer
DE60213232T2 (en) 2001-05-15 2007-07-26 Faulk Pharmaceuticals, Inc., Indianapolis TARGETED RELEASE OF MEDICAMENTS FOR THE TREATMENT OF VIRUS INFECTIONS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US5108987A (en) * 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
GB8519457D0 (en) * 1985-08-02 1985-09-11 Faulk Ward Page Tumour imaging agents
US5208021A (en) * 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5792458A (en) * 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
CA2016584C (en) * 1989-05-17 1999-06-29 Robert S. Greenfield Anthracycline conjugates having a novel linker and methods for their production
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals

Also Published As

Publication number Publication date
JP2004501171A (en) 2004-01-15
EP1305051A2 (en) 2003-05-02
AU2001271525A1 (en) 2002-01-08
WO2002000170A3 (en) 2002-08-08
WO2002000170A2 (en) 2002-01-03
EP1305051A4 (en) 2007-01-10
CA2414401A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
EP1427403B8 (en) Valproic acid for the treatment of breast cancer, colon cancer, head and neck cancer, small cell lung carcinoma and cancer of the blood cells in combination with irradiation
NO20015584L (en) Long-lasting insulin-tropic peptides and conjugates and use in the manufacture of medicaments for treatment
EP1586338A3 (en) The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
IL182352A (en) Use of et-743 in the preparation of a medicament for treating cancer and medical kits containing et-743
ATE235513T1 (en) OPIOID CONJUGATES WITH ENDOGENE CARRIER PROTEINS
DE69817602D1 (en) DRUG ADMINISTRATION SYSTEM WITH TWO-STAGE TARGETING
Alexiou et al. Therapeutic efficacy of ferrofluid bound anticancer agent
IL153586A0 (en) Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
EP1591450A4 (en) Conjugate for retention in blood and cancer tissue-specific drug delivery
DE602005026510D1 (en) Anthracyclinderivate
AR029160A1 (en) THE USE OF PEGILATED INTERFERON-ALFA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF RENAL CELL CARCINOMA, A KIT AND THE USE OF IT
Hryniuk Importance of chemotherapy scheduling: pieces of the puzzle
Hervonen et al. Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study
RU2003124139A (en) METHOD FOR PROLONGED DRUG THERAPY
Chin et al. Forthcoming articles and issues
Lee et al. Dental and nutritional management of the head and neck cancer patient
Boddy Regional Chemotherapy: Theory and Practice
Sparano et al. Increasing the efficacy of 5-fluorouracil with interferons: preclinical, clinical, and pharmacokinetic studies
RU99103901A (en) METHOD FOR MEDICINAL TREATMENT OF MALIGNANT TUMORS
Lokman et al. GENE THERAPY IN HEAD AND NECK CANCERS
UA4663U (en) Method for treating acute salpingoophoritis
SUNAKAWA et al. SUPERSELECTIVE RAPID INTRAARTERIAL INFUSION OF CARBOPLATIN PLUS RADIOTHERAPY FOR ORAL AND OROPHARYNGEAL CANCER
Bloomer et al. Forthcoming articles and issues
RU2002127274A (en) USE OF THE PREPARATION VETOM-7048 FOR THE FIRST TIME AS A MEDICINAL PRODUCT IN THE TREATMENT OF BRAIN ATROPHY, BRAIN HYDROCEPHALIA
RU2002129097A (en) COMBINED THERAPIES USING VASCULAR HARMFUL ACTIVITY